-
Posted: November 25th, 2019, 3:00am GMT
Conditions: Metastatic Cholangiocarcinoma; Metastatic Hepatocellular Carcinoma; Stage III Hepatocellular Carcinoma AJCC v8; Stage III Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIA Hepatocellular Carcinoma AJCC v8; Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIB Hepatocellular Carcinoma AJCC v8; Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8; Stage IV Hepatocellular Carcinoma AJCC v8; Stage IV Intrahepatic Cholangiocarcinoma AJCC v8; Stage IVA Hepatocellular Carcinoma AJCC v8; Stage IVB Hepatocellular Carcinoma AJCC v8; Unresectable Cholangiocarcinoma; Unresectable Hepatocellular Carcinoma; Unresectable Intrahepatic Cholangiocarcinoma
Interventions: Drug: Carboplatin; Drug: Paclitaxel; Drug: Pevonedistat
Sponsors: National Cancer Institute (NCI)
Active, not recruiting
-
Posted: November 21st, 2019, 3:00am GMT
Conditions: Pancreaticoduodenectomy
Interventions: Procedure: robotic pancreaticoduodenectomy
Sponsors: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Recruiting
-
Posted: November 15th, 2019, 3:00am GMT
Conditions: Advanced Colorectal Carcinoma; Metastatic Colorectal Carcinoma; Stage IV Colorectal Cancer AJCC v8; Stage IVA Colorectal Cancer AJCC v8; Stage IVB Colorectal Cancer AJCC v8; Stage IVC Colorectal Cancer AJCC v8; Stage II Colon Cancer; Stage II Rectal Cancer; Stage III Colon Cancer; Stage III Rectal Cancer; Esophageal Cancer; Pancreatic Cancer; Bile Duct Cancer; Gastric Cancer; Gall Bladder Cancer; Small Bowel Adenocarcinoma
Interventions: Biological: Bevacizumab; Drug: Dasatinib; Drug: Fluorouracil; Drug: Leucovorin; Drug: Leucovorin Calcium; Drug: Oxaliplatin; Other: Quality-of-Life Assessment
Sponsors: Anne Noonan
Active, not recruiting
-
Posted: November 8th, 2019, 3:00am GMT
Conditions: Advanced Solid Tumors; NSCLC; Bladder Cancer; HNSCC; Renal Cancer; Melanoma; Anal Cancer; Colorectal Cancer; Cholangiocarcinoma; Gastric Cancer; Hepatocellular Carcinoma; Merkel Cell Carcinoma; Cervical Cancer
Interventions: Drug: Continue PD-1/PD-L1 Inhibitors treatment; Other: Discontinue PD-1/PD-L1-1 inhibitor
Sponsors: Jason J. Luke, MD
Recruiting
-
Posted: November 5th, 2019, 3:00am GMT
Conditions: Squamous Cell Carcinoma of the Head and Neck; Renal Cell Carcinoma; Ovarian Cancer; Gastric Cancer; Esophageal Cancer; Lung Squamous Cell Carcinoma; Pancreatic Cancer; Bile Duct Cancer; Endometrial Cancer; Melanoma Cancer; Urothelial Cancer
Interventions: Drug: PF-06940434; Drug: PF-06801591
Sponsors: Pfizer
Active, not recruiting
-
Posted: November 4th, 2019, 3:00am GMT
Conditions: Gastric Cancer; Bladder Cancer; Squamous Non-small Cell Lung Cancer; Cholangiocarcinoma; Sarcoma; Endometrial Cancer; Other Solid Tumours
Interventions: Drug: CPL304110
Sponsors: Celon Pharma SA; National Center for Research and Development, Poland
Recruiting